CRISPR Therapeutics (CRSP) Highlights Strategic Priorities and Anticipated 2025 Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones
January 13, 2025 7:00 AM EST-Ongoing launch of CASGEVY® continues to gain momentum-
-2025 is poised to be a catalyst-rich year with key updates across several programs-
-Starting 2025 with a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities-
ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated 2025 milestones.
As we look ahead to 2025, we are in a... More
